Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
J Fr Ophtalmol ; 45(2): 216-232, 2022 Feb.
Artículo en Francés | MEDLINE | ID: mdl-34991909

RESUMEN

In recent years, research in artificial intelligence (AI) has experienced an unprecedented surge in the field of ophthalmology, in particular glaucoma. The diagnosis and follow-up of glaucoma is complex and relies on a body of clinical evidence and ancillary tests. This large amount of information from structural and functional testing of the optic nerve and macula makes glaucoma a particularly appropriate field for the application of AI. In this paper, we will review work using AI in the field of glaucoma, whether for screening, diagnosis or detection of progression. Many AI strategies have shown promising results for glaucoma detection using fundus photography, optical coherence tomography, or automated perimetry. The combination of these imaging modalities increases the performance of AI algorithms, with results comparable to those of humans. We will discuss potential applications as well as obstacles and limitations to the deployment and validation of such models. While there is no doubt that AI has the potential to revolutionize glaucoma management and screening, research in the coming years will need to address unavoidable questions regarding the clinical significance of such results and the explicability of the predictions.


Asunto(s)
Inteligencia Artificial , Glaucoma , Algoritmos , Técnicas de Diagnóstico Oftalmológico , Glaucoma/diagnóstico , Humanos , Pruebas del Campo Visual
2.
J Fr Ophtalmol ; 43(3): 256-270, 2020 Mar.
Artículo en Francés | MEDLINE | ID: mdl-32057527

RESUMEN

Ischemic optic neuropathies are among the leading causes of severe visual acuity loss in people over 50 years of age. They constitute a set of various entities that are clinically, etiologically and therapeutically different. Anatomically, it is necessary to distinguish anterior and posterior forms. From an etiological point of view, the diagnosis of the arteritic form due to giant cell arteritis requires emergent management to prevent blindness and even death in the absence of prompt corticosteroid treatment. When this diagnosis has been ruled out with certainty, non-arteritic ischemic optic neuropathies represent a vast etiological context that in the majority of cases involves a local predisposing factor (small optic nerves, disc drusen) with a precipitating factor (severe hypotension, general anesthesia or dialysis) in a context of vascular disease (sleep apnea syndrome, hypertension, diabetes, etc.). In the absence of specific available treatment, it is the responsibility of the clinician to identify the risk factors involved, in order to reduce the risk of contralateral recurrence that may occur even several years later. Due to their complexity, these pathologies are the subject of debates regarding both the pathophysiological and therapeutic perspectives; this review aims to provide a synthesis of validated knowledge while discussing controversial data.


Asunto(s)
Neuropatía Óptica Isquémica , Enfermedad Aguda , Anciano , Anciano de 80 o más Años , Ceguera/diagnóstico , Ceguera/etiología , Ceguera/terapia , Arteritis de Células Gigantes/complicaciones , Arteritis de Células Gigantes/diagnóstico , Arteritis de Células Gigantes/terapia , Humanos , Persona de Mediana Edad , Disco Óptico/patología , Neuropatía Óptica Isquémica/diagnóstico , Neuropatía Óptica Isquémica/etiología , Neuropatía Óptica Isquémica/terapia , Agudeza Visual/fisiología
3.
J Fr Ophtalmol ; 43(2): e41-e54, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31952875

RESUMEN

Ischemic optic neuropathies are among the leading causes of severe visual acuity loss in people over 50 years of age. They constitute a set of various entities that are clinically, etiologically and therapeutically different. Anatomically, it is necessary to distinguish anterior and posterior forms. From an etiological point of view, the diagnosis of the arteritic form due to giant cell arteritis requires emergent management to prevent blindness and even death in the absence of prompt corticosteroid treatment. When this diagnosis has been ruled out with certainty, non-arteritic ischemic optic neuropathies represent a vast etiological context that in the majority of cases involves a local predisposing factor (small optic nerves, disc drusen) with a precipitating factor (severe hypotension, general anesthesia or dialysis) in a context of vascular disease (sleep apnea syndrome, hypertension, diabetes, etc.). In the absence of specific available treatment, it is the responsibility of the clinician to identify the risk factors involved, in order to reduce the risk of contralateral recurrence that may occur even several years later. Due to their complexity, these pathologies are the subject of debates regarding both the pathophysiological and therapeutic perspectives; this review aims to provide a synthesis of validated knowledge while discussing controversial data.


Asunto(s)
Neuropatía Óptica Isquémica/diagnóstico , Neuropatía Óptica Isquémica/etiología , Neuropatía Óptica Isquémica/terapia , Enfermedad Aguda , Edad de Inicio , Anciano , Anciano de 80 o más Años , Ceguera/diagnóstico , Ceguera/epidemiología , Ceguera/etiología , Ceguera/terapia , Arteritis de Células Gigantes/complicaciones , Arteritis de Células Gigantes/diagnóstico , Arteritis de Células Gigantes/epidemiología , Arteritis de Células Gigantes/terapia , Humanos , Persona de Mediana Edad , Neuropatía Óptica Isquémica/epidemiología , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/epidemiología , Trastornos de la Visión/etiología , Trastornos de la Visión/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA